Biohaven's taldefgrobep alfa receives fda fast track designation for spinal muscular atrophy

-  taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in phase 3 development to increase muscle mass for spinal muscular atrophy patients now granted fast track in addition to previously receiving orphan drug designation in the us new haven, conn. , feb. 21, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking